Nymox Pharmaceutical Corp (NYMX) - Financial and Strategic SWOT Analysis Review

July 2021 | 34 pages | ID: N9F4F790375EN
GlobalData

Abstracts

Nymox Pharmaceutical Corp (NYMX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Nymox Pharmaceutical Corp (Nymox) is a biopharmaceutical company that develops therapeutics in the area of male health and diagnostic products. It is developing a drug candidate for treatment of Benign Prostatic Hyperplasia (BPH) and early-stage prostate cancer. The company markets diagnostic products for measuring tobacco product exposure and for the diagnosis of Alzheimer’s disease. Its diagnostic product portfolio includes N9icAlert test to determine smoking status; and TobacAlert home test to determine person’s level of exposure to tobacco products, including secondhand smoke. Nymox’s lead drug candidate, NX-1207 is intended for the treatment of BPH and for early-stage prostate cancer. The company markets and distributes its products across North America, Asia and Europe through its own marketing and distribution centers and medical representatives. Nymox is headquartered in Saint Laurent, Quebec, Canada.

Nymox Pharmaceutical Corp Key Recent Developments

Feb 06,2020: Nymox announces new appointment of Russell Thomson Ph.D. as Nymox Vice President of Quality and Regulatory Affairs

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Nymox Pharmaceutical Corp - Key Facts
Nymox Pharmaceutical Corp - Key Employees
Nymox Pharmaceutical Corp - Key Employee Biographies
Nymox Pharmaceutical Corp - Major Products and Services
Nymox Pharmaceutical Corp - History
Nymox Pharmaceutical Corp - Company Statement
Nymox Pharmaceutical Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Nymox Pharmaceutical Corp - Business Description
Geographical Segment: Canada
Performance
Geographical Segment: Europe & Other
Performance
Geographical Segment: Geographic regions
Overview
Geographical Segment: The US
Performance
R&D Overview
Nymox Pharmaceutical Corp - SWOT Analysis
SWOT Analysis - Overview
Nymox Pharmaceutical Corp - Strengths
Nymox Pharmaceutical Corp - Weaknesses
Nymox Pharmaceutical Corp - Opportunities
Nymox Pharmaceutical Corp - Threats
Nymox Pharmaceutical Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Nymox Pharmaceutical Corp, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 06, 2020: Nymox announces new appointment of Russell Thomson Ph.D. as Nymox Vice President of Quality and Regulatory Affairs

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Nymox Pharmaceutical Corp, Key Facts
Nymox Pharmaceutical Corp, Key Employees
Nymox Pharmaceutical Corp, Key Employee Biographies
Nymox Pharmaceutical Corp, Major Products and Services
Nymox Pharmaceutical Corp, History
Nymox Pharmaceutical Corp, Subsidiaries
Nymox Pharmaceutical Corp, Key Competitors
Nymox Pharmaceutical Corp, Ratios based on current share price
Nymox Pharmaceutical Corp, Annual Ratios
Nymox Pharmaceutical Corp, Annual Ratios (Cont...1)
Nymox Pharmaceutical Corp, Interim Ratios
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Nymox Pharmaceutical Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Nymox Pharmaceutical Corp, Performance Chart (2016 - 2020)
Nymox Pharmaceutical Corp, Ratio Charts
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021